Back to top
more

Argenx (ARGX)

(Delayed Data from NSDQ)

$877.72 USD

877.72
351,969

-14.54 (-1.63%)

Updated Jun 18, 2026 04:00 PM ET

After-Market: $877.31 -0.41 (-0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.00%
2Buy18.14%
3Hold10.18%
4Sell5.72%
5Strong Sell3.11%
S&P50011.49%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (149 out of 247)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

EXEL vs. ARGX: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

EXEL vs. ARGX: Which Stock Is the Better Value Option?

Zacks Equity Research

FDA Accepts RHHBY's sNDA for Gazyva in Treating Lupus Nephritis

by Zacks Equity Research

Roche's filing is based on data from a late-stage study that shows a complete renal response benefit in lupus nephritis patients who received Gazyva.

Zacks Equity Research

AXSM Gets Positive FDA Feedback for Alzheimer's Agitation Drug Filing

by Zacks Equity Research

Based on the FDA's feedback, Axsome plans to submit a supplemental NDA for AXS-05 in Alzheimer's disease agitation in third-quarter 2025.

Zacks Equity Research

NTLA's Q4 Loss Narrower Than Estimates, Revenues Increase Y/Y

by Zacks Equity Research

Intellia reports better-than-expected fourth-quarter 2024 results. The company provides updates on its pipeline candidates.

Zacks Equity Research

Rocket Pharmaceuticals Q4 Loss Narrower Than Estimates, Pipeline in Focus

by Zacks Equity Research

RCKT incurs a narrower-than-expected fourth-quarter 2024 loss. The company provides updates on its pipeline candidates.

Zacks Equity Research

Perrigo's Q4 Earnings Beat Estimates, Revenues Decline Y/Y

by Zacks Equity Research

PRGO reports mixed Q4 2024 results. The decline in the company's top line is due to the loss of sales stemming from exited businesses and product lines.

Zacks Equity Research

IOVA Q4 Earnings Beat, Stock Down on Looming Economic Uncertainty

by Zacks Equity Research

Iovance reports better-than-expected fourth-quarter results. The stock plunges on warnings of adverse macroeconomic factors harming its business.

Zacks Equity Research

CORT's Q4 Earnings and Revenues Fall Short of Estimates

by Zacks Equity Research

Corcept reports weaker-than-expected results for the fourth quarter of 2024. Korlym drives year-over-year sales.

Zacks Equity Research

MIRM's Q4 Loss Wider Than Expected, Revenues Beat Estimates

by Zacks Equity Research

Mirum's fourth-quarter 2024 earnings miss estimates while revenues beat the same.

Zacks Equity Research

Beam Therapeutics' Q4 Earnings & Revenues Beat Estimates

by Zacks Equity Research

BEAM incurs a narrower-than-expected loss in the fourth quarter. The company remains focused on pipeline development.